Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

7.000
+0.1001.45%
Volume:608.00K
Turnover:4.17M
Market Cap:5.71B
PE:-17.84
High:7.000
Open:6.880
Low:6.780
Close:6.900
52wk High:12.230
52wk Low:3.910
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.63
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.392
ROE:-7.76%
ROA:-5.07%
PB:1.38
PE(LYR):-17.84
PS:9.26

Loading ...

Madrigal Pharmaceuticals Enters Global Licensing Agreement with Suzhou Ribo for Liver Disease Programs

Deep News
·
Feb 11

ASCLETIS-B Selects Oral Amylin Receptor Agonist Peptide ASC36 for Clinical Development

Stock News
·
Feb 11

ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds

Stock News
·
Feb 10

ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential

Stock News
·
Feb 10

ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase

Stock News
·
Feb 09

Shanghai Sheng Sheng Abandons A-Shares for Hong Kong: Revenue Stagnation Reveals Growth Bottleneck, Controversy Surrounds Actual Controller's Equity Maneuvers

Deep News
·
Feb 06

Novartis Submits Application in China for Groundbreaking Autoimmune Drug

Stock News
·
Feb 06

Generic Drug Competition Intensifies, Novartis Forecasts 2026 Profit Decline

Stock News
·
Feb 04

Puli Pharmaceutical Claims Continue to Gather, Precedent Set for Successful Cases, More Investors Can Join

Deep News
·
Feb 03

ASCLETIS-B (01672) Proposes Placement of 69.256 Million Shares at Approximately 4% Discount, Targeting Net Proceeds of About HK$835.3 Million

Stock News
·
Feb 03

Nikkei Index Rises 0.4%, Driven by Auto and Pharma Stocks

Deep News
·
Feb 02

VIVA BIOTECH (01873): Langhua Pharmaceutical's Environmental Impact Report Gains Approval

Stock News
·
Jan 29

Ascletis Pharma-B (01672): First-in-Class Oral FASN Inhibitor Denifostat (ASC40) Achieves Positive Topline Results in Phase III Open-Label Acne Study

Stock News
·
Jan 29

Hong Kong Stocks Movement | Ascletis Pharma-B (01672) Rises Over 4% in Afternoon Trading as Company Initiates Patient Dosing for Diabetes Drug ASC30 Phase II Trial

Stock News
·
Jan 29

Novartis (NVS.US) siRNA Therapy "Inclisiran" Approved for New Indication

Stock News
·
Jan 28

Xiangxue Pharmaceutical Claims Now Accepting Registrations, Two Categories of Investors Eligible for Compensation

Deep News
·
Jan 28

Nikkei Index Drops 0.2%, Dragged Down by Auto and Pharma Stocks

Deep News
·
Jan 27

Insilico Medicine (03696) Enters into Over HKD 931 Million Drug R&D Collaboration with Qilu Pharmaceutical to Accelerate Innovative Therapies for Cardiovascular and Metabolic Diseases

Stock News
·
Jan 27

ASCLETIS-B (01672) Announces Completion of First Dosing in 13-Week US Phase II Study of Oral Small-Molecule GLP-1R Agonist ASC30 for Diabetes

Stock News
·
Jan 26

Tiankang Pharmaceutical's IPO: Defying Industry Recovery with Declining Performance, Capacity Data in Dispute, and Fundraising for Expansion Raises Questions

Deep News
·
Jan 23